It is teaming up with Geistlich Biomaterials Italia, which will help advance the clinical science supporting the OrthoPure
Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) has signed an exclusive multi-year agreement with Geistlich Biomaterials Italia, which will distribute the company’s OrthoPure XT ligament product in Italy.
The company said there was the potential to expand the tie-up to other geographies. No financial details were given.
Investors were told Geistlich said it will help advance the clinical science supporting OrthoPure, with the work conducted by leading Italian clinicians.
Tissue Regenix chief executive Daniel Lee said: “Geistlich is a leader in regenerative products, so our commitments are aligned in delivering innovative products to advance patient care.
“We are excited to work with them to build the clinical experience with OrthoPure XT and introduce this transformative product to the Italian medical community.”
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the…
